G1 Therapeutics to Participate in the Cowen 43rd Annual

G1 Therapeutics to Participate in the Cowen 43rd Annual

RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today......

G1 Therapeutics to Release Fourth Quarter and Full Year

G1 Therapeutics to Release Fourth Quarter and Full Year

RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a......

G1 Therapeutics Announces Top Line Results from Pivotal

G1 Therapeutics Announces Top Line Results from Pivotal

- PRESERVE 1 Achieved its Co-Primary Endpoints Showing Statistically Significant Reductions in Occurrence of Severe Neutropenia During Induction and......

G1 Therapeutics Announces Inducement Grants Under Nasdaq

G1 Therapeutics Announces Inducement Grants Under Nasdaq

RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today......

menu
menu